EOS Insert™

Potentia's first product containing POT-4 in a sustained delivery intravitreal implant formulation is called the EOS Insert. The insert is designed to be injected intravitreally through a 25-gauge syringe and to sustain a therapeutic concentration of POT-4 in the eye of the patient for a period of at least 12 months. The resulting drug product will be targeted at patients with either the dry or the wet forms of age-related macular degeneration.